Charles Schwab Investment Management Inc. Acquires 62,507 Shares of RxSight, Inc. (NASDAQ:RXST)

Charles Schwab Investment Management Inc. lifted its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 28.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 285,329 shares of the company's stock after acquiring an additional 62,507 shares during the period. Charles Schwab Investment Management Inc. owned 0.77% of RxSight worth $14,104,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Amalgamated Bank lifted its position in shares of RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company's stock worth $71,000 after acquiring an additional 207 shares during the period. Principal Financial Group Inc. raised its position in RxSight by 0.7% in the 3rd quarter. Principal Financial Group Inc. now owns 36,046 shares of the company's stock valued at $1,782,000 after purchasing an additional 240 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in RxSight by 3.2% in the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company's stock worth $473,000 after purchasing an additional 242 shares in the last quarter. RiverPark Advisors LLC raised its holdings in shares of RxSight by 9.6% in the second quarter. RiverPark Advisors LLC now owns 3,379 shares of the company's stock valued at $203,000 after buying an additional 297 shares during the last quarter. Finally, CWM LLC lifted its position in RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company's stock worth $25,000 after buying an additional 371 shares in the last quarter. 78.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on RXST. Needham & Company LLC reaffirmed a "buy" rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. UBS Group assumed coverage on RxSight in a research report on Friday. They set a "buy" rating and a $52.00 target price for the company. Finally, Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a "buy" rating and a $72.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight has an average rating of "Buy" and an average price target of $63.63.

Insider Activity at RxSight

In other news, insider Ilya Goldshleger sold 3,105 shares of RxSight stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $46.08, for a total transaction of $143,078.40. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at approximately $1,946,695.68. The trade was a 6.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Shweta Maniar sold 3,782 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the completion of the transaction, the director now directly owns 10,902 shares in the company, valued at $500,183.76. The trade was a 25.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,807 shares of company stock valued at $3,202,275. 9.36% of the stock is owned by insiders.

RxSight Stock Down 6.6 %

Shares of NASDAQ:RXST traded down $2.85 during midday trading on Monday, reaching $40.30. The company had a trading volume of 1,057,388 shares, compared to its average volume of 490,150. The business's 50 day moving average price is $48.01 and its 200 day moving average price is $51.53. The stock has a market cap of $1.62 billion, a PE ratio of -45.81 and a beta of 1.11. RxSight, Inc. has a 1-year low of $33.95 and a 1-year high of $66.54.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.